Andera Partners

Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

Sirsa, founded in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes, analyzing risks, and defining strategies to enhance operational sustainability. Sirsa provides a software-as-a-service platform for measuring companies' extra-financial footprint and impacts. It assists clients in implementing strategic initiatives, managing action plans, reporting results, and ensuring compliance with regulations. The firm serves a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental services, and software, among others.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

Allodiagnostic SAS, based in Paris, France, specializes in providing essential real estate diagnostics, including assessments for termites, electrical systems, and energy performance. Founded in 2001, the company caters to private individuals during the sale or rental of properties. It serves as a key resource for both consumers and real estate professionals, offering tailored solutions to meet various diagnostic requirements. As of July 2017, Allodiagnostic operates as a subsidiary of Edmond de Rothschild (France).

Finsecur S.A. is a French company based in Paris that specializes in the design, manufacture, and maintenance of fire-detection systems. Established in 2000, it offers a range of products including detectors, control panels, and accessories, as well as comprehensive fire alarm systems such as home fire detectors, extinguishing systems, and smoke clearing panels. Additionally, the company provides technical alarms for monitoring defects and anomalies in installations, including alarm panels and sprinkler system monitoring. Finsecur's products cater to various sectors, including clean rooms, telecoms, airports, and military industries. The company has been recognized for its innovation and growth, having received the BPI label Excellence, which connects it with a network of leading French companies in technology.

A2iA S.A. specializes in the development of advanced software tools for handwritten and machine-printed text recognition, information extraction, and intelligent document classification. Its product offerings include a2ia Mobility, which supports various workflows such as mobile remote deposit capture and ID verification; a2ia mNote, designed for offline conversion of handwritten notes into digital formats; and a2ia DocumentReader, which extracts data from both structured and unstructured documents. Additional tools include a2ia TextReader for transcribing printed and cursive handwriting, a2ia CheckReader for automated data capture from payment documents, and a2ia FieldReader for extracting information from forms. A2iA caters to a diverse clientele across sectors such as banking, fintech, telecom, healthcare, and government, serving markets in Europe, North America, Latin America, the Middle East, Africa, India, and the Asia Pacific. Founded in 1991 and headquartered in Paris, with an office in New York, A2iA operates as a subsidiary of Mitek Systems, Inc.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.